EE143 Cost-Effectiveness of Ocrelizumab in First-Line Treatment of Highly Active Relapsing-Remitting Multiple Sclerosis in Chile
To develop a cost-effectiveness analysis of ocrelizumab versus other first-line treatment alternatives (interferons, dimethyl fumarate, glatiramer acetate, teriflunomide, and fingolimod) for highly active relapsing-remitting multiple sclerosis from the perspective of the Chilean public health system.
Source: Value in Health - Category: International Medicine & Public Health Authors: E. V ásquez, P. Lasalvia, M. Rozas, C. Gejman Source Type: research
More News: Chile Health | Copaxone | Gilenya | International Medicine & Public Health | Multiple Sclerosis